Citius Pharmaceuticals shares jumped 22.12% after hours following the commercial launch of its LYMPHIR therapy and a fiscal 2025 business update.

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than ...

The latest price target for Citius Pharmaceuticals (NASDAQ:CTXR) was reported by D. Boral Capital on December 4, 2025. The analyst firm set a price target for $6.00 expecting CTXR to rise to within 12 ...

Citius Pharma (CTXR) has delivered a -77.150% change over the past year, with a 52-week range between 0.630 and 5.950. What Is the Average Daily Trading Volume of Citius Pharma (CTXR)? The average ...

CTXR is trading near the bottom of its 52-week range and below its 200-day simple moving average. Price change The price of CTXR shares has decreased $0.02 since the market last closed. This is a 1.87 ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...